|
Market Closed -
Nasdaq
16:00:00 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 46.99 USD | -22.39% |
|
-20.87% | +11.14% |
Company Valuation: Nektar Therapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,493 | 424.8 | 107.8 | 171.5 | 860 | 1,604 | - | - |
| Change | - | -82.96% | -74.63% | 59.16% | 401.35% | 86.55% | - | - |
| Enterprise Value (EV) 1 | 1,759 | -80.2 | 72.51 | 127.3 | 860 | 1,516 | 1,394 | 1,208 |
| Change | - | -104.56% | 190.41% | 75.56% | 575.63% | 76.31% | -8.07% | -13.36% |
| P/E | -4.72x | -1.15x | -0.39x | -1.6x | -4.35x | -5.81x | -4.58x | -4.42x |
| PBR | 3.69x | 1.16x | 0.83x | 3.15x | - | 1.97x | 4.3x | 4.04x |
| PEG | - | 0x | 0x | 0x | -0.4x | 0.3x | -0.2x | -1.18x |
| Capitalization / Revenue | 24.5x | 4.61x | 1.2x | 1.74x | 15.6x | 38.3x | 28.1x | 45.7x |
| EV / Revenue | 17.3x | -0.87x | 0.8x | 1.29x | 15.6x | 36.2x | 24.5x | 34.4x |
| EV / EBITDA | -4.07x | 0.22x | -0.28x | -0.9x | -6.18x | -6.31x | -3.49x | -2.77x |
| EV / EBIT | -3.94x | 0.21x | -0.27x | -0.87x | -6.14x | -6.38x | -3.92x | -2.96x |
| EV / FCF | -4.11x | 0.26x | -0.37x | -0.72x | -4.12x | -6.47x | -7.78x | -3.41x |
| FCF Yield | -24.3% | 386% | -267% | -139% | -24.3% | -15.5% | -12.9% | -29.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -42.9 | -29.55 | -21.75 | -8.7 | -9.73 | -8.087 | -10.25 | -10.64 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 101.9 | 92.06 | 90.12 | 98.43 | 55.23 | 41.88 | 57 | 35.13 |
| EBITDA 1 | -432.3 | -363.1 | -255.9 | -141.2 | -139.1 | -240.4 | -399.4 | -435.4 |
| EBIT 1 | -446.4 | -376.2 | -263.7 | -145.6 | -140.1 | -237.7 | -355.7 | -407.8 |
| Net income 1 | -523.8 | -368.2 | -276.1 | -119 | -164.1 | -244.7 | -353.7 | -406.1 |
| Net Debt 1 | -734 | -505 | -35.28 | -44.25 | - | -88.02 | -210.4 | -396.6 |
| Reference price 2 | 202.65 | 33.90 | 8.47 | 13.95 | 42.28 | 46.99 | 46.99 | 46.99 |
| Nbr of stocks (in thousands) | 12,304 | 12,530 | 12,718 | 12,297 | 20,342 | 34,143 | - | - |
| Announcement Date | 2/28/22 | 2/28/23 | 3/4/24 | 3/12/25 | 3/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.49x | 47.26x | -8.23x | -.--% | 2.07B | |
| 21.73x | 7.77x | 15.61x | 1.37% | 74.46B | |
| 31.25x | 9.01x | 28.06x | 0.04% | 60.14B | |
| 33.64x | 6.03x | 18.07x | 0.97% | 48.15B | |
| 34.63x | 3.34x | 14.4x | -.--% | 44.25B | |
| -21.16x | 229.18x | -22.81x | -.--% | 43.99B | |
| 47.94x | 5.54x | 30.43x | -.--% | 41.61B | |
| 26.89x | 7.76x | 19.96x | 0.42% | 29.97B | |
| 33.91x | 7.26x | 18.84x | -.--% | 29.31B | |
| -70.02x | 13.44x | -68.51x | -.--% | 24.93B | |
| Average | 13.13x | 33.66x | 4.58x | 0.28% | 39.89B | |
| Weighted average by Cap. | 19.44x | 31.96x | 10.14x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NKTR Stock
- Valuation Nektar Therapeutics
Select your edition
All financial news and data tailored to specific country editions
